Myriad Genetics Inc (NASDAQ:MYGN): Stock Big Money Feel Good About: at 1.37

May 3, 2018 - By Maria Fierro

Myriad Genetics, Inc. (NASDAQ:MYGN) Corporate Logo

“Big money” Positions

“Big money sentiment for Myriad Genetics Inc (NASDAQ:MYGN) in Q4 2017 increased to 1.37, revealed SEC filings. That’s up 0.51, from 2017Q3’s 0.86. 118 investment professionals opened new or increased equity positions, while 86 cut down and sold equity positions in Myriad Genetics Inc so the sentiment is positive. These funds own 71.43 million shares, that’s down from 71.79 million shares in 2017Q3. Funds holding Myriad Genetics Inc in top 10 decreased from 4 to 1 for a decrease of 3. 19 Investors Sold All; 67 Reduced Holdings; 72 increased stakes while 46 investment professionals bought stakes.

Most Myriad Genetics Inc Investors

As of Q4 2017 Tieton Capital Management Llc has 3.67% invested in Myriad Genetics Inc. Myriad Genetics Inc’s shareholder S&T Bank Pa owns 476,156 shares as of Q4 2017. Camber Capital Management Llc reported 1.50 million shares. Taylor Frigon Capital Management Llc revealed 43,777 shares position in Myriad Genetics Inc. The California-based fund Aimz Investment Advisors Llc holds 43,785 shares or 1.13% of their US equity exposure.

Myriad Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide.The firm is valued at $1.94 billion. The firm offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BART, a DNA sequencing test for hereditary breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.14.87 is the P/E ratio. It also provides COLARIS, a DNA sequencing test for colorectal and uterine cancer; COLARIS AP, a DNA sequencing test for colorectal cancer; Vectra DA, a protein quantification test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer; and EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer.

MYGN is reaching $27.72 during the last trading session, after decreased 1.28%.Currently Myriad Genetics, Inc. is uptrending after 52.68% change in last May 3, 2017. MYGN has also 79,202 shares volume. The stock outperformed the S&P 500 by 41.13%.

The Connecticut-based Point72 Asset Mgmt Ltd Partnership has invested 0.13% in Myriad Genetics, Inc. (NASDAQ:MYGN). Stifel Financial Corporation stated it has 0.01% in Myriad Genetics, Inc. (NASDAQ:MYGN). Dupont Cap Management Corp accumulated 32,480 shs or 0.03% of the stock. Voya Inv Mngmt Ltd Liability Co holds 0% or 40,043 shs. State Of Tennessee Treasury Department invested 0.01% of its capital in Myriad Genetics, Inc. (NASDAQ:MYGN). 211,014 are held by New York State Common Retirement Fund. Federated Pa, a Pennsylvania-based fund reported 3,664 shs. Wells Fargo & Mn owns 904,595 shs. Moreover, Aperio Group Lc has 0% invested in Myriad Genetics, Inc. (NASDAQ:MYGN). Bamco New York stated it has 185,000 shs or 0.03% of all its holdings. Acadian Asset Management Limited Co accumulated 2.21M shs or 0.33% of the stock. Blackrock Inc has 0.02% invested in Myriad Genetics, Inc. (NASDAQ:MYGN) for 10.07 million shs. Tower Cap (Trc) has 264 shs. Schwab Charles Mngmt invested in 0.02% or 660,729 shs. Hall Laurie J Trustee owns 0% invested in Myriad Genetics, Inc. (NASDAQ:MYGN) for 200 shs.

Myriad Genetics, Inc. had 7 selling transactions and 0 insider buys since December 11, 2017. This’s net activity of $5.48 million. 13,759 shs were sold by MARSH RICHARD M, worth $498,764. GILBERT WALTER PHD sold $248,925 worth of Myriad Genetics, Inc. (NASDAQ:MYGN) on Thursday, December 14. $201,000 worth of Myriad Genetics, Inc. (NASDAQ:MYGN) was sold by DREISMANN HEINRICH.

Myriad Genetics, Inc. (NASDAQ:MYGN) Ratings Coverage

Total analysts of 9 have positions in Myriad Genetics (NASDAQ:MYGN) as follows: 2 rated it a “Buy”, 1 with “Sell” and 6 with “Hold”. The positive are 22%. Since November 8, 2017 according to StockzIntelligence Inc Myriad Genetics has 13 analyst reports. On Wednesday, February 7 the firm has “Hold” rating given by Jefferies. On Wednesday, November 8 the firm has “Hold” rating by Deutsche Bank given. The company rating was upgraded by Morgan Stanley on Wednesday, March 21. On Tuesday, February 6 the firm has “Hold” rating by Piper Jaffray given. On Wednesday, February 7 the rating was maintained by Leerink Swann with “Market Perform”. In Tuesday, January 2 report Stephens maintained it with “Buy” rating and $45.0 target. On Wednesday, February 7 the firm has “Buy” rating by BTIG Research given. On Monday, January 22 the stock of Myriad Genetics, Inc. (NASDAQ:MYGN) earned “Hold” rating by Barclays Capital. On Wednesday, February 7 the rating was maintained by Morgan Stanley with “Underweight”. The company rating was maintained by Morgan Stanley on Wednesday, November 8.

Myriad Genetics, Inc. (NASDAQ:MYGN) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.